Salivary Gland Secretion (SGS)

Molecular Composition & Functional Architecture

Last Updated: March 1, 2026Reviewed by: Andrei Dokukin, MD

This page presents the biochemical composition and molecular properties of medicinal leech SGSry gland secretion (SGS). Discussion of biological mechanisms does not imply therapeutic efficacy outside FDA-cleared contexts. Data are sourced from peer-reviewed biochemistry, proteomics, and genomics literature spanning 1884–2024.

The salivary gland secretion (SGS) of Hirudo medicinalis is the molecular foundation of hirudotherapy. Over 130 million years of coevolution with vertebrate hemostatic systems have produced a secretion containing more than 100 identified bioactive molecules — with two genome assemblies (Kvist et al., 2020; Babenko et al., 2020) and integrated proteomics-transcriptomics (Liu et al., 2019) revealing 434 full-length protein sequences, including 44 confirmed bioactive proteins across six functional categories: analgesic/anti-inflammatory, extracellular matrix degradation, platelet inhibition, anticoagulant, antimicrobial, and other functions. SGS composition includes direct thrombin inhibitors, factor Xa inhibitors, platelet adhesion and aggregation inhibitors, thrombolytic enzymes, spreading factors, antimicrobial peptides, protease inhibitors spanning the coagulation/fibrinolytic/complement/inflammatory cascades, and a diverse array of lipid mediators, ion modulators, and neurotrophic factors. Three FDA-approved pharmaceuticals — bivalirudin, desirudin, and dabigatran — trace their molecular origins directly to this secretion.

Historical Discovery

The scientific investigation of SGS spans 141 years, from Haycraft's first observation that leech secretion prevents blood coagulation to modern multi-omics approaches that have identified over 200 proteins in the saliva.

Year	Investigator	Milestone	Significance
1884	Haycraft (Edinburgh)	Discovery of anticoagulant secretion	First proof that leech SGS contains a “ferment antagonistic to the ferment of the blood”; identified unicellular glands in anterior sucker
1937	Claude	Histamine-like vasodilatory activity	Demonstrated that leech extracts produce vasodilation analogous to histamine, enhancing bite-site blood flow
1955	Markwardt (Erfurt)	Isolation of pure hirudin	First purification from leech head extracts; established thrombin-specific mechanism; named the compound
1969	Fritz et al.	Bdellins A & B isolated	First protease inhibitors from leeches — trypsin and plasmin inhibition
1977	Seemuller et al.	Eglins b/c discovered	Potent neutrophil elastase and cathepsin G inhibitors — foundation for anti-inflammatory understanding
1984–91	Baskova & Nikonov	SGS collection method; destabilase discovery	Salt-induced emesis method (patented 1994); discovered destabilase isopeptidase; documented seasonal variation
1987	Rigbi et al. (Jerusalem)	Phagostimulation method	Arginine-based blood substitute for SGS collection; identified eglin-like activity and factor Xa inhibition
1990–91	Seymour; Munro	Decorsin and calin characterized	GP IIb/IIIa antagonist (decorsin) and collagen adhesion inhibitor (calin) — completing the antiplatelet picture
1994	Sommerhoff; Sollner	LDTI and hirustasin	Kazal-type inhibitors of mast cell tryptase and tissue kallikrein — broadened anti-inflammatory profile
2000	Zavalova et al.	Destabilase dual function confirmed	Single 12.3 kDa protein exhibits both isopeptidase (thrombolytic) and lysozyme (antibacterial) activities
2001	Baskova et al.	Continuous-flow SGS collection	Contamination-free method; revealed temporal variation — most potent peptides released in first minutes of feeding
2019	Liu et al.	Integrated proteomics-transcriptomics	434 full-length proteins; 44 confirmed bioactive; 221 bioactive transcripts — vastly exceeding classical biochemistry
2020	Kvist; Babenko & Baskova	Two genome assemblies	176.96 Mbp genome; 15 anticoagulation factors + 17 antihemostatic proteins; discovered M12/M13 proteases, CRISP, cystatins, ficolins
2022	Hohmann et al.	Tandem-Hirudin discovered	First oligomeric hirudin superfamily member — two globular domains, no thrombin inhibition, suggesting functional diversification

Haycraft's Original Observation (1884)

“It is possible that leeches secrete a juice containing a ferment antagonistic to the ferment of the blood, preventing blood coagulation. This juice appears in sufficient quantity around the edges of the wound made by the leech to prevent for a time the coagulation of the issuing blood.”

Haycraft identified elongated epithelial cells penetrating the muscular layer of the anterior sucker — groups of unicellular glands — and demonstrated that “the skin lining the anterior sucker and the anterior portion of the medicinal leech was equally active in preventing blood coagulation.” This 1884 observation launched a scientific pursuit that continues 141 years later with genomic and AI-driven approaches.

SGS Collection Methods

Native SGS collection is technically demanding. The three established methods produce secretions of differing purity and composition, with direct implications for research reproducibility and pharmaceutical standardization.

Method	Developer	Principle	Purity	Yield	Limitation
Salt-induced emesis	Baskova, 1994 (patent)	Concentrated saline excites serotonin-rich neurons → emetic reflex → SGS expelled from fasting leech	High (native, uncontaminated)	Low volume per leech	Requires fasting leeches; variable yield
Phagostimulation	Rigbi et al., 1987	0.01 M arginine blood substitute → upper lip chemoreceptor stimulation → feeding + SGS ejection	Low (intestinal contamination)	Higher volume (A₂₈₀ = 0.197)	Contains intestinal proteases; not true SGS
Continuous-flow	Baskova et al., 2001	Modified Rigbi — saline continuously stirred and renewed during feeding → prevents swallowing SGS-enriched solution	High (no intestinal contamination)	Good volume, sequential fractions	Technical setup complexity

Temporal Variation During Feeding

The continuous-flow method (Baskova et al., 2001) revealed a critical finding: SGS composition changes throughout the feeding process. Sequential UV spectral analysis showed that characteristic absorption peaks shift toward longer wavelengths as feeding progresses. During the initial minutes, the secretion contains the predominant mass of peptides and proteins absorbing in the short-wavelength region — the most potent anticoagulant and anti-adhesive compounds. In subsequent fractions, only trace amounts remain. This temporal pattern indicates that the leech delivers its most pharmacologically active molecules during the first minutes of feeding, providing the rapid anticoagulant activity needed to initiate blood flow.

Whole Leech Extracts (WLE) vs. Native SGS

Many investigators have used cephalic region extracts rather than native SGS, including Markwardt's original hirudin isolation (1955). WLE contains protease inhibitors concentrated not in SGS but in intestinal canal walls (Roters & Zebe, 1992), blood lacunae, reproductive organs, nephridia, and mucus — making it a more comprehensive but less specific collection than SGS alone. WLE is the basis for the pharmaceutical formulation Piyavit (Chapters 18–19). A 5 kDa protein termed pseudohirudin was identified in body trunk extracts but lacks antithrombin activity (Baskova et al., 1980).

Complete Molecular Catalog

The following table compiles all characterized SGS components with molecular weights (mature processed forms), biological targets, mechanisms, clinical significance, primary references, and pharmaceutical development status. Components are organized by functional category.

Over 200 proteins have been identified via proteomics; those awaiting full biochemical characterization are listed at the end of the table.

Component	MW (kDa)	Target	Mechanism	Key Reference	Pharma Status
Anticoagulant & Antithrombotic
Hirudin	7.0	Thrombin (active site + exosite 1)	Direct thrombin inhibitor; K_d = 2 × 10⁻¹⁴ M; blocks fibrinogen clotting, FV/VIII/XIII activation, platelet aggregation	Haycraft 1884; Markwardt 1955	Bivalirudin (FDA 2000), Desirudin (FDA 2003), Dabigatran (FDA 2010)
Hirudin-like factor 3	~7	Thrombin (variant binding)	Alternative thrombin inhibitor; structural diversity suggests functional specialization	Kvist et al. 2020	None
Antistasin	15	Factor Xa	Serine protease inhibitor; blocks prothrombinase assembly	Rigbi et al. 1995	Research stage
Lefaxin	~14	Factor Xa	Alternative FXa inhibitor	Kvist et al. 2020	None
Ghilanten	~13	Factor XIIIa	Inhibits fibrin cross-linking (transglutaminase); prevents fibrin stabilization	Finney et al. 1997	None
LCI	~7	Carboxypeptidase B (TAFIa)	Prevents C-terminal lysine removal from fibrin; maintains fibrinolytic susceptibility	Reverter et al. 1998	None
Antiplatelet
Calin	65	Collagen (types I, III)	Inhibits collagen-mediated platelet adhesion (NOT aggregation); key to prolonged post-bite bleeding	Munro et al. 1991	None
Saratin	12	vWF-collagen interaction	Blocks von Willebrand factor-dependent platelet adhesion to collagen	Barnes et al. 2001	Research stage
Decorsin	4.4	GP IIb/IIIa (RGD motif)	Platelet aggregation inhibitor via integrin blockade	Seymour et al. 1990	Analogs (research)
Apyrase	~40	Extracellular ADP	Hydrolyzes ADP released from activated platelets; removes aggregation stimulus	Rigbi et al. 1996	None
PAF inhibitor	<1 (lipid)	PAF receptor	Phosphoglyceride antagonist of platelet-activating factor	Hu-Am & Orevi 1992	None
LMW Ca²⁺ modulators	<0.5	Receptor-dependent Ca²⁺ channels; Na⁺ channels	Suppresses receptor-dependent Ca²⁺ entry into platelets; inhibits Na⁺-mediated depolarization	Afanasyeva et al. 1999	None
Thrombolytic
Destabilase-M (isopeptidase)	12.3	ε-(γ-Glu)-Lys bonds in stabilized fibrin	Monomerises D-dimer; dissolves cross-linked fibrin resistant to conventional thrombolytics; neurotrophic at 10⁻¹² M	Baskova & Nikonov 1985	Recombinant (preclinical)
Anti-Inflammatory & Protease Inhibitors
Eglins b/c	8.1	Elastase, cathepsin G, chymotrypsin, subtilisin	Anti-inflammatory protease inhibition; potentiates glucocorticoids; neurotrophic at low concentrations	Seemuller et al. 1977	Research stage
Bdellins A/B	A: 6.3; B: 20	Trypsin, plasmin, acrosin	Protease inhibition; bdellin-B neurotrophic: 60% neurite growth at 0.05 ng/mL	Fritz et al. 1969	None
Bdellastatin	6.3	Trypsin, Factor Xa	Antistasin-family dual inhibitor; neurotrophic: 48% neurite growth at 0.01 ng/mL	Strube et al. 1993	None
Hirustasin	5.9	Kallikrein, trypsin, chymotrypsin, cathepsin G	Antistasin-type serine protease inhibitor; kinin pathway modulation	Sollner et al. 1994	None
LDTI	4.7	Mast cell tryptase, trypsin	Kazal-type inhibitor; reduces mast cell-mediated inflammation	Sommerhoff et al. 1994	Research stage
Guamerin	5.6	Neutrophil elastase	Elastase-specific inhibitor	Jung et al. 1995	None
Piguamerin	~6	Elastase, trypsin	Dual protease inhibitor	Kvist et al. 2020	None
C1s complement inhibitor	67	Complement C1s	Blocks classical complement pathway; protects symbiotic Aeromonas from lysis	Baskova et al. 1988	None
Kininases	Variable	Bradykinin, kinins	Degradation of pain mediators; local analgesic effect at bite site	Baskova et al. 1984	None
Tissue Penetration & Remodeling
Hyaluronidase (orgelase)	28.5	Hyaluronic acid β(1→4) bonds	Depolymerises extracellular matrix; “spreading factor” facilitating SGS penetration; edema drainage	Linker 1960; Claude 1937	Orgelase (Biopharm patent)
Collagenase	~100	Collagen fibrils	ECM degradation; tissue remodeling at bite site	Baskova et al. 1984	None
Histamine-like compound	<0.5	H1, H2 receptors	Vasodilation; increased capillary permeability; enhanced blood flow	Claude 1937	None
Antimicrobial
Destabilase-L (lysozyme)	12.3	Bacterial peptidoglycan	Muramidase; gram-positive bactericidal; same protein as destabilase-M (dual activity)	Zavalova et al. 2000	None
Theromyzin / Theromacin / Peptide B	8–14	Bacterial membranes	Antimicrobial peptides; broad-spectrum activity; wound infection prevention	Tasiemski et al. 2004	None
Lipid Mediators & Small Molecules
6-Keto-PgF1α	<0.5	Prostacyclin receptors	Stable prostacyclin metabolite; antiaggregant + vasodilator	Baskova & Nikonov 1987	None (endogenous analog)
Phosphatidylcholine / fatty acids	Variable	Cell membranes	Liposomal structure; enables oral bioavailability (pinocytosis); basis for Piyavit	Rabinowitz 1996	Piyavit (oral)
Acetylcholine	0.15	Muscarinic/nicotinic receptors	Vasodilation; local blood flow enhancement	Babenko et al. 2020	None (endogenous)
Lipase / cholesterol esterase	~45	Triglycerides; cholesterol esters	Lipid hydrolysis; anti-atherosclerotic potential; lipid metabolism regulation	Baskova et al. 1984	Active in Piyavit
Genomics-Era Discoveries (2019–2024)
Cystatins	~13	Cysteine proteases	Protease inhibition; tissue protection; anti-inflammatory	Kvist/Babenko 2020	None
Ficolins	~35	Pathogen carbohydrate patterns	Innate immune modulation; lectin pathway complement activation	Kvist et al. 2020	None
CRISP proteins	~25	Ion channels	Vascular smooth muscle tone modulation; possible vasodilatory contribution	Babenko et al. 2020	None
M12/M13 proteases	Variable	Bioactive peptides	Processing and activation of secretory peptides; SGS maturation	Babenko et al. 2020	None
Adenosine deaminase (ADA)	~40	Adenosine	Converts adenosine → inosine; purinergic signaling modulation; immunomodulation	Babenko et al. 2020	None
Tandem-Hirudin	~14	Unknown (NOT thrombin)	First oligomeric hirudin superfamily member; two globular domains; no thrombin inhibition — functional diversification	Hohmann et al. 2022	None
Pseudohirudin	5.0	None identified	Found in body trunk (not SGS); lacks antithrombin activity; function unknown	Baskova et al. 1980	None

Functional Architecture: Anticoagulant Cascade

SGS targets the coagulation cascade at every level — from initiation through fibrin stabilization. This multi-point blockade ensures that no single resistance mechanism in the host can overcome the anticoagulant effect.

Thrombin Inhibition — Hirudin

Hirudin (7.0 kDa, 65 amino acids, 3 disulfide bonds) is the most potent natural thrombin inhibitor known. It binds thrombin with a K_d of 2 × 10⁻¹⁴ M (20 femtomolar) through a unique bivalent mechanism: the N-terminal globular domain occupies the active-site cleft while the anionic C-terminal tail (sulfated Tyr⁶³) binds exosite 1. This dual engagement blocks all thrombin functions: fibrinogen clotting, factor V/VIII/XIII activation, and thrombin-induced platelet aggregation.

Factor Xa Inhibition — Antistasin & Lefaxin

Antistasin (15 kDa) and lefaxin (~14 kDa) block factor Xa, preventing prothrombinase complex assembly — the critical amplification step that converts prothrombin to thrombin. This targets the cascade upstream of thrombin, reducing thrombin generation rather than merely inhibiting existing thrombin. Originally identified by Tuszynski et al. (1987) in Haementeria officinalis; subsequently reported in Hirudo by Rigbi, Jackson, and Atamna (1995); lefaxin identified genomically (Kvist et al., 2020).

Fibrin Stabilization Blockade — Ghilanten

Ghilanten (~13 kDa, Finney et al., 1997) inhibits factor XIIIa (transglutaminase), preventing the cross-linking of fibrin monomers into the stable fibrin mesh. Without cross-linking, the thrombus remains susceptible to fibrinolytic dissolution — synergizing with destabilase's thrombolytic action on already-stabilized clots.

Fibrinolytic Susceptibility — LCI

The leech carboxypeptidase inhibitor (LCI, ~7 kDa, Reverter et al., 1998) inhibits carboxypeptidase B / TAFIa (thrombin-activatable fibrinolysis inhibitor). TAFIa normally removes C-terminal lysines from fibrin, making it resistant to plasminogen binding and fibrinolysis. LCI maintains these lysine residues, preserving the thrombus's susceptibility to the body's endogenous fibrinolytic system.

Cascade Coverage Summary

Initiation: Factor Xa inhibition (antistasin, lefaxin) → reduced thrombin generation
Amplification: Direct thrombin inhibition (hirudin) → blocks all downstream effects
Stabilization: Factor XIIIa inhibition (ghilanten) → prevents fibrin cross-linking
Resolution: TAFIa inhibition (LCI) → maintains fibrinolytic susceptibility
Thrombolysis: Isopeptidase activity (destabilase) → dissolves already-stabilized fibrin

Functional Architecture: Antiplatelet Cascade

Six SGS components create multi-layered blockade of the platelet adhesion-activation-aggregation cascade — targeting virtually every step.

Platelet Step	SGS Inhibitor	Target	Mechanism
1. Adhesion (collagen)	Calin (65 kDa)	Collagen types I, III	Blocks collagen-mediated platelet adhesion; does NOT inhibit aggregation
2. Adhesion (vWF)	Saratin (12 kDa)	vWF-collagen binding	Prevents von Willebrand factor-dependent adhesion under high shear
3. Activation (ADP)	Apyrase (~40 kDa)	Extracellular ADP	Hydrolyzes ADP released from dense granules; removes aggregation stimulus
4. Activation (PAF)	PAF inhibitor (<1 kDa)	PAF receptor	Phosphoglyceride blocks mast cell-mediated platelet activation
5. Activation (Ca²⁺)	LMW Ca²⁺ modulators (<0.5 kDa)	Receptor-dependent Ca²⁺/Na⁺ channels	Suppresses intracellular calcium signaling from thrombin and PAF
6. Aggregation	Decorsin (4.4 kDa)	GP IIb/IIIa integrin	RGD-motif peptide blocks the final common pathway of aggregation
7. Aggregation (thrombin)	Hirudin (7.0 kDa)	Thrombin	Blocks thrombin-induced platelet aggregation (secondary to DTI activity)

Redundancy Demonstration

Baskova et al. (1987) demonstrated that when hirudin is depleted through repeated SGS collection without intervening blood meals, the secretion retains the ability to block platelet adhesion and intrinsic pathway coagulation. This proves that hirudin is not the sole anticoagulant determinant — calin, saratin, antistasin, the LMW Ca²⁺ modulators, and other components provide redundant protection. The evolutionary advantage is clear: no single host resistance mechanism can overcome the multi-target blockade.

Functional Architecture: Anti-Inflammatory

SGS contains the broadest spectrum of protease inhibitors found in any single biological secretion — targeting the coagulation, fibrinolytic, inflammatory, and complement cascades simultaneously.

Neutrophil Protease Inhibition

Eglins b/c (8.1 kDa, Seemuller et al., 1977) inhibit neutrophil elastase, cathepsin G, chymotrypsin, and subtilisin. They potentiate glucocorticoid activity and exhibit neurotrophic properties at low concentrations. Guamerin (5.6 kDa, Jung et al., 1995) provides additional elastase-specific inhibition. Piguamerin (~6 kDa, Kvist et al., 2020) is a dual elastase/trypsin inhibitor identified genomically. Together, these compounds block the tissue-destructive proteases released by activated neutrophils at sites of inflammation.

Mast Cell Tryptase Inhibition

LDTI (leech-derived tryptase inhibitor, 4.7 kDa, Sommerhoff et al., 1994) is a Kazal-type inhibitor that blocks mast cell tryptase — a key mediator of immediate hypersensitivity, bronchoconstriction, and tissue remodeling. Hirustasin (5.9 kDa, Sollner et al., 1994) additionally inhibits tissue kallikrein, modulating the kinin pathway that drives pain and vascular permeability. Together with kininases (which degrade bradykinin directly), these compounds create the analgesic effect observed at the leech bite site.

Complement System Blockade

The C1s complement inhibitor (67 kDa, Baskova et al., 1988; Tikhonenko, 2000) blocks the classical complement pathway at its initiation point. SGS also blocks the alternative complement pathway. The evolutionary purpose is dual: (1) protecting the leech's own tissues from complement-mediated attack during feeding, and (2) protecting the symbiotic Aeromonas bacteria in the leech gut from complement-mediated lysis. The therapeutic implication is complement-mediated inflammation reduction at the treatment site.

Fibrinolytic Pathway Modulation

Bdellins A/B (6.3/20 kDa, Fritz et al., 1969) inhibit trypsin and plasmin. Bdellastatin (6.3 kDa, Strube et al., 1993) is an antistasin-family dual inhibitor of trypsin and factor Xa. Both bdellins and bdellastatin exhibit significant neurotrophic properties: bdellin-B promotes 60% neurite growth at 0.05 ng/mL, and bdellastatin promotes 48% neurite growth at 0.01 ng/mL — concentrations far below their protease inhibition thresholds.

Multi-Target Protease Inhibition Profile

In 1987, Baskova, Nikonov, Mirkamalova, Zinenko, and Kozlov identified the capacity of SGS to block both classical and alternative complement pathways. Combined with inhibition of the coagulation (hirudin, antistasin, lefaxin), fibrinolytic (bdellins), and inflammatory (eglins, LDTI, guamerin) cascades, this represents a protease inhibition breadth unmatched in any other known biological secretion. It mirrors the multi-target approach of the entire SGS and explains why hirudotherapy produces systemic effects extending far beyond simple anticoagulation.

Destabilase: Thrombolytic Enzyme

Destabilase is the only known enzyme in nature capable of cleaving ε-(γ-Glu)-Lys isopeptide bonds in cross-linked (stabilized) fibrin — the bonds created by factor XIIIa that make mature thrombi resistant to conventional fibrinolytic therapy.

Dual Enzymatic Activity

Zavalova et al. (2000) demonstrated that a single 12.3 kDa protein has two distinct enzymatic activities:

Destabilase-M (isopeptidase): Cleaves ε-(γ-Glu)-Lys bonds in D-dimer → monomerises cross-linked fibrin
Destabilase-L (lysozyme): Muramidase activity → hydrolyzes bacterial peptidoglycan → gram-positive bactericidal

This dual function — thrombolytic + antibacterial in one molecule — is unique in enzymology.

Recombinant Destabilase

Kurdyumov et al. (2021) produced three recombinant destabilase isoforms and demonstrated that they dissolve human blood clots in vitro. Crystal structure was resolved at 1.1 Å resolution — the highest resolution for any leech-derived protein. Both isopeptidase and lysozyme activities were retained in the recombinant form, confirming the feasibility of pharmaceutical development.

Neurotrophic Activity

Destabilase exhibits neurotrophic effects at extraordinarily low concentrations — 10⁻¹² M (picomolar). At these concentrations, it promotes neurite outgrowth in cultured neurons, suggesting a function entirely distinct from its thrombolytic activity. This neurotrophic capacity is shared with bdellins and bdellastatin, indicating that SGS protease inhibitors may have dual roles in tissue repair and neural recovery.

Seasonal Availability

The isopeptidase (thrombolytic) activity of destabilase virtually disappears during autumn-winter and reappears in May, remaining high through September (Baskova et al., 1984). This seasonal variation has direct clinical implications: leeches used during winter provide robust antithrombin activity but reduced thrombolytic capacity, while summer leeches offer the full complement of both activities.

Tissue Penetration & Spreading Mechanism

SGS must penetrate host tissues rapidly to deliver its bioactive payload into the microcirculatory bed. Three components facilitate this process.

Hyaluronidase (Orgelase)

28.5 kDa enzyme that depolymerises hyaluronic acid via a unique β(1→4) glucuronidic bond specificity — in contrast to all known mammalian hyaluronidases, which cleave β(1→3) bonds (Linker, Meyer & Hoffman, 1960). First described as a “spreading factor” by Nobel laureate Albert Claude (1937), who demonstrated that intradermal injection of leech extract produced 418-fold greater tissue penetration than testicular hyaluronidase in rabbit skin (7,112 cm² vs 17 cm² ink spread area). Purified by Yuki & Fishman (1963); confirmed unable to hydrolyze chondroitin and its derivatives, unlike β-hyaluronidases. Thermally stable (withstands 1 h at 50°C), active across a wide pH range, and — critically for clinical applications — not inhibited by heparin (unlike testicular hyaluronidase), enabling concurrent use with anticoagulant therapy. Patented by Biopharm (Roy Sawyer, 1988) as Orgelase for cardiovascular and ophthalmological applications, leveraging its anti-ischaemic properties and heparin compatibility as a tissue-penetrating drug delivery agent.

Collagenase

~100 kDa enzyme that degrades collagen fibrils in the extracellular matrix (Baskova et al., 1984). Works synergistically with hyaluronidase: while hyaluronidase removes the ground substance between collagen fibrils, collagenase degrades the fibrils themselves. This dual ECM breakdown enables deep tissue penetration by other SGS components.

Histamine-Like Vasodilator

A low-molecular-weight compound (<0.5 kDa) that activates H1 and H2 receptors, producing vasodilation and increased capillary permeability (Claude, 1937). This enhances blood flow to the bite site and creates the sustained vasodilation observed during and after feeding. Combined with acetylcholine (identified by Babenko et al., 2020) and 6-keto-PgF1α (prostacyclin metabolite; Baskova & Nikonov, 1987), SGS provides triple vasodilatory redundancy.

Antimicrobial Defense

SGS antimicrobial activity serves a dual evolutionary purpose: preventing infection at the bite wound (protecting the host's blood meal from contamination) and maintaining the leech's gut microbiome.

Destabilase-L (Lysozyme)

The same 12.3 kDa destabilase protein that exhibits isopeptidase (thrombolytic) activity also functions as a muramidase — hydrolyzing bacterial cell wall peptidoglycan. This dual-function enzyme provides gram-positive bactericidal activity at the bite site while simultaneously dissolving cross-linked fibrin. The lysozyme activity was confirmed by Zavalova et al. (2000) and retained in all three recombinant isoforms (Kurdyumov et al., 2021).

Antimicrobial Peptides

Tasiemski et al. (2004) characterized three antimicrobial peptides from Hirudo medicinalis: theromyzin, theromacin, and peptide B (8–14 kDa). These membrane-active peptides provide broad-spectrum antimicrobial protection at the bite wound. Their presence explains why leech bite infections are relatively rare despite the deliberate introduction of Aeromonas bacteria from the leech gut.

Complement Evasion Strategy

The C1s complement inhibitor (67 kDa) serves a fascinating evolutionary role: it protects the leech's symbiotic Aeromonas hydrophila bacteria from complement-mediated lysis during feeding. Without this protection, the host's complement system would destroy the bacteria that the leech depends on for blood digestion. This same mechanism produces anti-inflammatory effects at the clinical treatment site.

Aeromonas Paradox

The medicinal leech harbors Aeromonas hydrophila / A. veronii as obligate gut symbionts. These bacteria produce enzymes essential for blood meal digestion but are potentially pathogenic to humans. SGS antimicrobial peptides partially control bacterial load at the bite site, but prophylactic antibiotics (fluoroquinolones or trimethoprim-sulfamethoxazole) are standard clinical practice. See the dedicated Aeromonas management page for protocols.

Seasonal Variation & Clinical Implications

SGS composition is not static — it varies by season, collection frequency, and feeding state, with direct implications for clinical standardization.

Parameter	Spring/Summer (May–Sep)	Autumn/Winter (Oct–Apr)	Clinical Implication
Antithrombin activity (hirudin)	Moderate	Higher	Winter leeches may provide stronger anticoagulation
Thrombolytic activity (destabilase isopeptidase)	High (present May–Sep)	Virtually absent	Summer leeches offer thrombolytic + anticoagulant; winter leeches anticoagulant only
Overall SGS complement	Full activity spectrum	Reduced thrombolytic component	Biofactory protocols should account for seasonality in product standardization

Collection Frequency Effects

Repeated SGS collection at one-month intervals without intervening blood meals shows a clear depletion pattern (Baskova et al., 1984):

Collections 1–2: High antithrombin activity
Collection 3: Sharp decline in antithrombin activity
Collection 4: Antithrombin activity disappears entirely
After blood meal: Full activity restored

Critically, antiplatelet and intrinsic pathway inhibition persist even when hirudin is fully depleted — confirming redundant anticoagulant mechanisms.

Temporal Feeding Variation

The continuous-flow method (Baskova et al., 2001) demonstrated that SGS composition changes during a single feeding session. Sequential UV spectral analysis showed absorption peaks shifting toward longer wavelengths as feeding progresses:

First minutes: Maximum peptide/protein concentration (short-wavelength UV absorption) — most potent anticoagulant delivery
Subsequent fractions: Trace amounts only
Final fraction (15th): Minimal bioactive content

This “front-loading” strategy delivers the most critical anticoagulant molecules within the first minutes of attachment.

Low-Molecular-Weight Ion Modulators

Receptor-Dependent Ion Channel Modulation

The LMW fraction (<500 Da) of SGS produces highly specific effects on platelet ion transport (Afanasyeva et al., 1999):

Ion Channel	SGS LMW Effect	Comparison to Losartan
Receptor-dependent Ca²⁺ entry (platelets)	Suppressed (thrombin & PAF response)	Similar effect
Receptor-dependent Na⁺ depolarization	Suppressed	Not reported for losartan
Receptor-independent Ca²⁺ efflux (erythrocytes)	No effect	Altered by losartan
Ca²⁺-dependent K⁺ channels (erythrocytes)	No effect	Altered by losartan

This selectivity for receptor-dependent (but not receptor-independent) ion transport suggests that the LMW fraction acts at the receptor level rather than on the ion channels themselves — a mechanism distinct from conventional calcium channel blockers. The molecular identity of these modulators remains to be elucidated.

Lipid Pharmacology

SGS contains a surprisingly high lipid concentration — 3.26 mg per 100 mL of secretion (Rabinowitz, 1996) — with functional significance for both antiplatelet activity and pharmaceutical formulation.

Lipid Composition

Total lipids: 3.26 mg / 100 mL SGS
Neutral lipids: ~2/3 of total
Polar lipids: ~1/3 of total
Phosphatidylcholine: Significant quantities; enables liposomal structure formation
Free fatty acids: Present in significant amounts
Phosphoglyceridol: Functions as PAF antagonist — inhibits PAF-stimulated platelet aggregation (Hu-Am & Orevi, 1992)

Oral Bioavailability & Piyavit

The lipid content of SGS may enable formation of liposomal structures that facilitate oral absorption via pinocytosis — penetrating from the intestine into the bloodstream (Baskova & Nikonov, 1986). This property is the pharmacological foundation for Piyavit, the oral pharmaceutical formulation derived from whole leech extract. Piyavit was registered in Russia (1994, re-registered 2001) specifically for treatment and prevention of superficial vein thrombophlebitis.

Prostacyclin Metabolite

In 1987, Baskova and Nikonov detected prostaglandins in SGS in the form of 6-keto-prostaglandin F1α, a stable metabolite of prostacyclin (PGI₂). Prostacyclin is the most potent endogenous inhibitor of platelet aggregation and a powerful vasodilator. Its presence in SGS adds an additional antiaggregant and vasodilatory pathway — complementing hirudin (anti-thrombin), calin (anti-adhesion), and decorsin (anti-aggregation).

Lipase & Cholesterol Esterase

SGS contains lipase (~45 kDa) and cholesterol esterase activities (Baskova et al., 1984) that catalyze hydrolysis of triglycerides and cholesterol esters. These enzymes are implicated in the anti-atherosclerotic properties observed in clinical studies (detailed in the atherosclerosis mechanisms page). They are also an active component of the Piyavit oral formulation.

DNA Methylation & Epigenetic Effects

Epigenetic Modification by SGS

Nikonov et al. (1990) demonstrated a remarkable epigenetic effect: SGS stimulates a 39% increase in 5-methylcytosine content in rat liver DNA within one hour of intraperitoneal perfusion. Key features:

Magnitude: 39% increase in global DNA methylation
Speed: Detectable within 1 hour
Reversibility: Fully reversed within 24 hours
Tissue: Demonstrated in liver (systemic effect)

DNA methylation is a fundamental epigenetic mechanism that regulates gene expression without altering the DNA sequence. A transient, reversible increase in methylation could modulate inflammatory gene expression, cellular differentiation, and tissue repair pathways. This finding represents one of the earliest demonstrations of a pharmacologically induced, reversible epigenetic modification — predating the modern field of epigenetic therapeutics by decades. The specific SGS component responsible and the gene targets affected remain unidentified, representing a significant research opportunity.

Absence of Nonspecific Proteolytic Activity

What SGS Does NOT Do

No caseinolytic activity (Rigbi et al., 1987)
Cannot activate plasminogen to plasmin
Cannot dissolve non-stabilized fibrin (Baskova & Nikonov, 1985)
Cannot hydrolyze plasmin-specific chromogenic substrate (D-Val-Leu-Lys paranitroanalide)
No broad-spectrum proteolytic activity at any season

Why This Matters

The absence of generalized proteolytic activity is as important as the specific enzyme activities present. A secretion containing broad-spectrum proteases would destroy its own bioactive components — hirudin, calin, destabilase, eglins — before they could exert their effects. The evolutionary solution is elegant: SGS contains highly specific hydrolases (destabilase targets only ε-(γ-Glu)-Lys bonds; hyaluronidase targets only HA β(1→4) bonds) but no generalized proteases, ensuring that all bioactive proteins survive intact in the wound microenvironment.

Genomic Revolution: From Biochemistry to Multi-Omics

Classical biochemistry identified ~30–40 SGS components. Modern genomics, transcriptomics, and proteomics have expanded this to >200 proteins — transforming our understanding of the medicinal leech as a pharmacological resource.

Study	Method	Key Findings	Novel Components
Liu et al. (2019)	Proteome + transcriptome integration	434 full-length protein sequences; 44 confirmed bioactive; 221 bioactive transcripts; 6 functional categories	Multiple novel proteins across all 6 categories
Kvist et al. (2020)	Genome assembly (H. medicinalis)	176.96 Mbp on 19,929 scaffolds; median coverage 146.78×; 15 anticoagulation factors; 17 antihemostatic proteins	Hirudin-like factor 3, lefaxin, piguamerin, ficolins, cystatins
Babenko et al. (2020)	RNA-seq on salivary cells (3 species)	Comparative salivary transcriptome across H. medicinalis, H. orientalis, H. verbana	M12/M13 proteases, CRISP proteins, apyrase, ADA, cystatins, ficolins, acetylcholine
Hohmann et al. (2022)	Structural biology	Tandem-Hirudin: first oligomeric hirudin superfamily member from Hirudinaria manillensis	Two globular domains in tandem; lacks C-terminal tail; NO thrombin inhibition
Guan et al. (2024)	Proteome + transcriptome (starvation)	Starvation-induced changes in SGS composition of Hirudo nipponia	Demonstrated that nutritional state modulates SGS protein expression

Scale of Discovery

Classical biochemistry (1884–2004): ~30–40 components characterized
Proteomics/transcriptomics (2019): 434 full-length proteins identified
Genomics (2020): 15 anticoagulation + 17 antihemostatic genes encoded
Total identified to date: >200 distinct proteins
Functionally characterized: <50 (≈25%)
Exploited pharmaceutically: ~5 (≈2.5%)

Species Comparison

Babenko et al. (2020) — co-authored by I.P. Baskova, author of the foundational text — performed comparative RNA-seq across three medicinal leech species. While the core anticoagulant toolkit (hirudin, destabilase, calin) is conserved, significant differences in CRISP protein expression, M12/M13 protease profiles, and antimicrobial peptide repertoires were observed between species. These differences may have clinical relevance: H. verbana (the species most commonly supplied in the US) and H. medicinalis (the European standard) may deliver subtly different SGS compositions.

Pharmaceutical Legacy

The medicinal leech is the source organism for three FDA-approved pharmaceuticals — making it one of the most successful examples of zoopharmaceutical drug discovery in modern medicine.

Drug	SGS Progenitor	FDA Approval	Indication	Status
Bivalirudin (Angiomax)	Hirudin → 20-aa synthetic analog	2000	PCI anticoagulation (ACC/AHA Class I for STEMI)	Generic available; $596M peak revenue; projected $887M by 2030
Desirudin (Iprivask)	Recombinant hirudin (65 aa)	2003	DVT prophylaxis in hip replacement	Available (limited use)
Dabigatran (Pradaxa)	Hirudin → non-peptide DTI (oral)	2010	AF stroke prevention; VTE treatment/prevention	$3.5B annual revenue; launched DOAC revolution

Pipeline Candidates

Recombinant destabilase: Thrombolytic + antibacterial; crystal structure at 1.1 Å; dissolves human clots in vitro (preclinical)
Decorsin analogs: GP IIb/IIIa antagonists for antiplatelet therapy (research)
Saratin: Anti-adhesion for arterial thrombosis prevention (research)
Eglin c analogs: Anti-inflammatory protease inhibition (research)
Orgelase (hyaluronidase): Cardiovascular/ophthalmological applications (patented)
Novel hirudin variants: K_i 0.323 nM computationally designed (preclinical)

Zoopharmaceutical Context

Among all animal-derived pharmaceuticals, the medicinal leech holds a unique position. Of six FDA-approved drugs derived from or inspired by animal venoms and secretions, three originate from the medicinal leech. For comparison: cone snails contributed one (ziconotide), Gila monster one (exenatide), and pit vipers one (captopril inspiration). The leech's disproportionate contribution reflects both the pharmacological richness of SGS and the 141-year research tradition following Haycraft's discovery.

The Unexploited Pharmacopeia

Of the >200 proteins identified in leech SGS by modern proteomics, fewer than 50 have been functionally characterized and only ~5 have been exploited pharmaceutically. Approximately 97.5% of the identified SGS proteome remains untapped as a drug discovery resource.

Known Unknowns

Pseudohirudin (5 kDa): hirudin homologue with no antithrombin activity — function unknown since 1980
Tandem-Hirudin: oligomeric hirudin family member that does NOT inhibit thrombin — what does it do?
CRISP proteins (~25 kDa): ion channel modulators of unknown specificity
Ficolins (~35 kDa): innate immune modulators — therapeutic potential unexplored
M12/M13 proteases: SGS maturation enzymes — could they be exploited for pro-drug activation?
Adenosine deaminase: purinergic signaling modulator — immunomodulatory potential

Future Discovery Approaches

Complete genome annotation: Finish functional annotation of all 434 identified protein sequences
AI-driven drug design: Use SGS compound scaffolds as starting points for computational optimization
Species comparison: Systematically compare SGS across H. medicinalis, H. verbana, H. orientalis, and non-medicinal species
Single-cell transcriptomics: Identify which salivary gland cell types produce which compounds
Cryo-EM structural biology: Resolve 3D structures of all major SGS proteins for structure-based drug design
Clinical-grade standardization: Develop validated assay panels for SGS quality control

The SGS of Hirudo medicinalis represents one of the most pharmacologically rich biological secretions in the animal kingdom. Its systematic characterization, still far from complete, continues to reveal molecules with potential therapeutic applications extending well beyond anticoagulation. ASH supports continued investment in SGS research as a foundation for evidence-based practice and pharmaceutical innovation.

Key SGS Characterization Studies

Landmark studies in SGS molecular characterization, 1884–2024
Study	Design	Population (n=)	Intervention	Key Outcome	Result
Haycraft JB 1884	Biochemical characterization	Hirudo medicinalis SGS (n=NR)	Extraction and bioassay	Anticoagulant activity	First demonstration leech secretion prevents coagulation; identified unicellular glands. Proc R Soc Lond
Markwardt F 1955	Biochemical characterization	Hirudo medicinalis SGS (n=NR)	Extraction and purification	Thrombin inhibition	First isolation of pure hirudin; thrombin-specific inhibition confirmed. Hoppe-Seyler Z Physiol Chem
Fritz H et al. 1969	Biochemical characterization	Hirudo medicinalis SGS (n=NR)	Extraction and purification	Protease inhibition	Discovery of bdellin A (6.3 kDa) and B (20 kDa); trypsin/plasmin inhibition. Hoppe-Seyler Z Physiol Chem
Seemuller U et al. 1977	Biochemical characterization	Hirudo medicinalis SGS (n=NR)	Extraction and purification	Neutrophil elastase / cathepsin G inhibition	Isolation of eglins b/c (8.1 kDa); neutrophil elastase and cathepsin G inhibition. Hoppe-Seyler Z Physiol Chem
Baskova IP & Nikonov GI 1985	Biochemical characterization	Hirudo medicinalis SGS (n=NR)	Extraction and enzymatic assay	Fibrinolytic / isopeptidase activity	Discovery of destabilase isopeptidase — first enzyme cleaving ε-(γ-Glu)-Lys bonds in stabilized fibrin. Biokhimiya
Baskova IP et al. 1987	In vitro / preclinical	Hirudo medicinalis SGS (n=NR)	Hirudin-depleted SGS fraction bioassay	Antiplatelet and intrinsic pathway inhibition	Hirudin-depleted SGS retains antiplatelet and intrinsic pathway inhibition — redundant anticoagulant mechanisms demonstrated. Biokhimiya
Rigbi M et al. 1987	Biochemical characterization	Hirudo medicinalis SGS (n=NR)	Phagostimulation collection (arginine-based)	Eglin-like and anticoagulant activities	Developed arginine-based phagostimulation method; confirmed eglin-like and anticoagulant activities in collected secretion. Comp Biochem Physiol
Seymour JL et al. 1990	Biochemical characterization	Macrobdella decora SGS (n=NR)	Extraction and purification	Platelet GP IIb/IIIa integrin antagonism	Discovery of decorsin (4.4 kDa, RGD motif) — platelet GP IIb/IIIa integrin antagonist. J Biol Chem
Munro R et al. 1991	Biochemical characterization	Hirudo medicinalis SGS (n=NR)	Extraction and purification	Platelet adhesion inhibition	Characterization of calin (65 kDa) — collagen-mediated platelet adhesion inhibitor; key mechanism for prolonged post-bite bleeding. Blood Coagul Fibrinolysis
Baskova IP et al. 2001	Biochemical characterization	Hirudo medicinalis SGS (n=NR)	Contamination-free phagostimulation collection	SGS composition during feeding	Contamination-free collection method developed; SGS composition varies during feeding — most potent peptides released in first minutes. Bioorg Khim
Zavalova LL et al. 2000	Biochemical characterization	Hirudo medicinalis SGS (n=NR)	Recombinant expression and enzymatic assay	Dual isopeptidase / lysozyme activity	Destabilase exhibits both isopeptidase (thrombolytic) and lysozyme (antibacterial) activities in a single 12.3 kDa protein. Biochemistry (Moscow)
Liu J et al. 2019	Proteomics/transcriptomics	Hirudo nipponia SGS (n=NR)	RNA-seq + proteomics	Protein identification	434 full-length protein sequences identified; 44 confirmed bioactive proteins and 221 bioactive transcripts across 6 categories. J Proteomics
Kvist S et al. 2020	Genome assembly	Hirudo medicinalis SGS (n=NR)	Whole-genome sequencing and annotation	Antihemostatic gene catalog	Genome assembly: 176.96 Mbp on 19,929 scaffolds; 15 anticoagulation factors and 17 antihemostatic proteins annotated. Sci Rep
Babenko VV et al. 2020	Proteomics/transcriptomics	3 Hirudo species SGS (n=NR)	Salivary cell RNA-seq	Novel secreted protein discovery	RNA-seq across 3 species; discovered M12/M13 proteases, CRISP proteins, apyrase, ADA, cystatins, and ficolins. BMC Genomics
Hohmann V et al. 2022	Biochemical characterization	Hirudinaria manillensis SGS (n=NR)	Recombinant expression and structural analysis	Hirudin superfamily structure	First oligomeric hirudin superfamily member — two globular domains in tandem; no thrombin inhibition despite structural similarity. Parasitol Res
Kurdyumov AS et al. 2021	In vitro / preclinical	Hirudo medicinalis SGS (n=NR)	Recombinant expression and clot dissolution assay	Thrombolytic and antibacterial activity	Three recombinant destabilase isoforms dissolved human blood clots; crystal structure resolved at 1.1 A; thrombolytic and antibacterial activities retained. Curr Issues Mol Biol

Evidence Gaps & Research Priorities

Despite 141 years of investigation, SGS characterization remains incomplete. The total number of identified proteins now exceeds 200 (Liu et al., 2019), but functional roles have been established for fewer than 50. Key research priorities include:

Functional Characterization

Over 150 proteins identified via proteomics await biochemical characterization
CRISP proteins, ficolins, and M12/M13 proteases have unknown therapeutic relevance
Tandem-Hirudin's function (despite hirudin homology but no thrombin activity) is unknown
Pseudohirudin (5 kDa, no antithrombin activity) — function unresolved since 1980

Standardization & Translation

Seasonal variation complicates dosing standardization for clinical use
Species differences (H. medicinalis vs H. verbana vs H. orientalis) insufficiently characterized
No validated assay panel for SGS quality control in clinical-grade leeches
AI-driven drug design from SGS scaffolds remains unexplored